Covid-19 roundup: FDA au­tho­rizes Pfiz­er/BioN­Tech vac­cine for 12- to 15-year-olds; No­vavax shares sink as com­pa­ny de­lays vac­cine time­line

Back-to-school sea­son could look much dif­fer­ent this year, as Pfiz­er and BioN­Tech’s Covid-19 vac­cine has be­come the first in the US to be au­tho­rized for chil­dren as young as 12 years old.

On Mon­day, the FDA ex­pand­ed its emer­gency use au­tho­riza­tion for the jab — which was orig­i­nal­ly OK’d for those 16 years and old­er — based on ef­fi­ca­cy da­ta from 190 ado­les­cents which showed their im­mune re­sponse to the vac­cine was at least as good as the re­sponse seen in old­er par­tic­i­pants.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER